AstraZeneca reaffirms 2026 outlook for low double-digit core EPS growth at constant exchange rates
AZN•AstraZeneca reiterated its 2026 outlook for mid-to-high single-digit revenue growth and low double-digit core EPS growth at constant exchange rates, with a core tax rate of 18%-22%. Nine-month revenue rose 7% to $46.88 billion and core EPS increased 14% to $8; its $80 billion 2030 revenue target remains on track.
1. Outlook reaffirmed
AstraZeneca reiterated its 2026 guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth, both at constant exchange rates. The company expects a core tax rate of 18%-22%.
2. Nine-month results
Revenue for the first nine months rose 7% to $46.88 billion at constant exchange rates, while core EPS increased 14% to $8. AstraZeneca said its $80 billion revenue target for 2030 remains on track.
